Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection

doi:10.1016/0042-6822(91)90034-9

Virology

Volume 180, Issue 1, January 1991, Pages 294-305

https://doi.org/10.1016/0042-6822(91)90034-9 Get rights and content

Abstract

Four recombinant vaccinia viruses were engineered for expression of different portions of the Japanese encephalitis virus (JEV) open reading frame. All four recombinant vaccinias contained the NS1 and NS2A genes, and each of these viruses specified the synthesis, glycosylation, and secretion of the nonstructural glycoprotein (NS1). All four recombinants also contained the E gene, and each virus correctly directed the synthesis and glycosylation of the envelope glycoprotein (E). Interestingly, two of these viruses (vP555 and vP650), which expressed the prM gene in addition to E and NS1, produced an extracellular hemagglutinin containing M and E that migrated in sucrose gradients similarly to the slowly-sedimenting hemagglutinin found in the culture fluid of JEV-infected cells. Immunization of 3-week-old mice with the recombinant viruses vP555 and vP658 resulted in immune responses to NS1, whereas only the virus that directed the synthesis of extracellular forms of E (vP555) induced an immune response to E. Both viruses provided protection against lethal challenge with JEV. Animals given two inoculations with vP555 were fully protected from greater than 10,000 LD₅₀ of JEV. This high level of protection was correlated with the production of high titers of neutralizing and hemagglutination-inhibiting antibodies.

References (48)

W. Fan et al.
Membrane association and secretion of the Japanese encephalitis virus NS1 protein from cells expressing NS1 cDNA
Virology
(1990)
C.A. Gibson et al.
Prospects for a virus non-structural protein as a subunit vaccine
Vaccine
(1988)
C.H. Huang
Studies of Japanese encephalitis in China
Adv. Virus Res.
(1982)
P.W. Mason
Maturation of Japanese encephalitis virus glycoproteins produced by infected mammalian and mosquito cells
Virology
(1989)
P.W. Mason et al.
Expression of Japanese encephalitis virus antigens in Escherichia coli
Virology
(1987)
Y. Matsuura et al.
Characterization of Japanese encephalitis virus envelope protein expressed by recombinant baculoviruses
Virology
(1989)
P.C. McAda et al.
Partial nucleotide sequence of the Japanese encephalitis virus genome
Virology
(1987)
T. Nowak et al.
Analysis of the terminal sequences of West Nile virus structural proteins and of the in vitro translation of these proteins allow the proposal of a complete scheme of the proteolytic cleavages involved in their synthesis
Virology
(1989)
P.K. Russell et al.
Chemical and antigenic structure of flaviviruses
D. Shapiro et al.
Change involving a viral membrane glycoprotein during morphogenesis of group B arboviruses
Virology
(1972)

R.E. Shope

Medical significance of togaviruses: An overview of diseases caused by togaviruses in man and in domestic and wild vertebrate animals

G. Winkler et al.

Evidence that the mature form of the flavivirus nonstructural protein NS1 is a dimer

Virology

(1988)

W.E. Brandt

Current approaches to the development of dengue vaccines and related aspects of the molecular biology of flaviviruses

J. Infect. Dis.

(1988)

M. Bray et al.

Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis

J. Virol.

(1989)

D.H. Clarke et al.

Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses

Amer. J. Trop. Med. Hyg.

(1958)

V. Deubel et al.

Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue

J. Gen. Virol.

(1988)

M.-F. Dubois et al.

Excretion of hepatitis B surface antigen particles from mouse cells transformed with cloned viral DNA

K.H. Eckels et al.

Virion and soluble antigens of Japanese encephalitis virus

Infect. Immun.

(1975)

B. Fallout et al.

Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a

J. Virol.

(1989)

E.A. Gould et al.

Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice

J. Gen. Virol.

(1986)

P. Guo et al.

Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals

J. Virol.

(1989)

S. Haishi et al.

Expression of envelope glycoprotein (E) of Japanese encephalitis virus by recombinant vaccinia virus

Acta Virol.

(1989)

E.A. Henchal et al.

Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus

J. Gen. Virol.

(1988)

B.M. Kaufman et al.

Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection

Amer. J. Trop. Med. Hyg.

(1989)

Cited by (178)

Advances in vaccinia virus-based vaccine vectors, with applications in flavivirus vaccine development
2022, Vaccine
Citation Excerpt :
Recombinants that co-expressed the genes for the structural glycoproteins, prM, and E elicited a high level of neutralizing (NEUT) and hemagglutination inhibiting (HAI) antibodies in mice and protected mice from a lethal challenge by JEV. These results demonstrate that recombinants expressing prM and E, instead of NS1, elicited higher levels of protective immunity [55,57,58]. Second, a replication-competent, but not incompetent, VV is critical for eliciting sterile protective immune responses.
Historically, virulent variola virus infection caused hundreds of millions of deaths. The smallpox pandemic in human beings has spread for centuries until the advent of the attenuated vaccinia virus (VV) vaccine, which played a crucial role in eradicating the deadly contagious disease. Decades of exploration and utilization have validated the attenuated VV as a promising vaccine vehicle against various lethal viruses. In this review, we focus on the advances in VV-based vaccine vector studies, including construction approaches of recombinant VV, the impact of VV-specific pre-existing immunity on subsequent VV-based vaccines, and antigen-specific immune responses. More specifically, the recombinant VV-based flaviviruses are intensively discussed. Based on the publication data, this review aims to provide valuable insights and guidance for future VV-based vaccine development.
Evaluation of Japanese encephalitis virus E and NS1 proteins immunogenicity using a recombinant Newcastle disease virus in mice
2020, Vaccine
Citation Excerpt :
However, due to severe drawbacks and limitations, the production of mouse brain-derived killed-inactivated vaccine was halted in 2006 [24,26]. In addition, recombinant protein-based vaccines, [27–30], plasmid DNA-based vaccines [31], and poxvirus-based vaccines [31–34] are also used with variable efficacy in animal models. Various viral vectors are explored to express foreign genes for recombinant vaccine production [35].
Japanese encephalitis (JE) is the most important cause of acute encephalitis syndrome (AES). Japanese encephalitis virus (JEV), the prototype member of the JE serocomplex, belongs to the genus Flavivirus. The immunogenic proteins envelope (E) and non-structural protein 1 (NS1) of JEV are widely explored for the development of vaccines and diagnostics against JEV. However, there are underlying concerns such as the risk of reversion of live-attenuated vaccines to high virulence, the incomplete inactivation of pathogens in inactivated vaccines and partial vaccine coverage. Newcastle disease virus (NDV) is an efficient viral vaccine vector to express several human and animal immunogenic proteins. In the present study, we have developed a recombinant NDV (rNDV), individually expressing the E and NS1 proteins of JEV (rNDV-Ejev and rNDV-NS1jev). The recovered rNDV-Ejev and rNDV-NS1jev were characterized in 9-day-old SPF embryonated chicken eggs and in cell culture. The vaccination of rNDV-Ejev and rNDV-NS1jev showed effective immunity against JEV upon intranasal immunization in BALB/c mice. The rNDVs vaccination produced effective neutralization antibody titers against both NDV and JEV. The cytokine profiling of the vaccinated mice showed an effective Th1 and Th2 mediated immune response. The study also provided an insight that E, when used in combination with NS1 could reduce the efficacy of only E based immunization in mice. Our results suggested rNDV-Ejev to be a promising live viral vectored vaccine against JEV. This study implies an alternative and economical strategy for the development of a recombinant vaccine against JEV.
Development of a serodiagnostic IgM-ELISA for tick-borne encephalitis virus using subviral particles with strep-tag
2018, Ticks and Tick-borne Diseases
Tick-borne encephalitis virus (TBEV) is a zoonotic agent causing severe encephalitis in humans. IgM antibody detection is useful for the serological diagnosis of TBEV infection, because IgM has high specificity for each flavivirus and indicates a recent infection. Commercial IgM-ELISA kits are somewhat expensive and difficulties in their sensitivity have been suggested due to their format and formalin-inactivated antigens. Therefore, the development of an inexpensive IgM-ELISA with high specificity and sensitivity is needed. In this study, a μ-capture ELISA was developed to detect TBEV-specific IgM antibodies using subviral particles (SPs) with strep-tag (strep-SP-IgM-ELISA). The results of our strep-SP-IgM-ELISA were highly correlated with diagnoses made by the neutralization test (sensitivity: 94.1%), and our strep-SP-IgM-ELISA could detect anti-TBEV IgM antibodies in patients who could not be diagnosed with the neutralization test. Besides, 51 of 52 positive samples by a commercial IgM-ELISA were also diagnosed as positive by our strep-SP-IgM-ELISA (98.1%), and our strep-SP-IgM-ELISA could detect anti-TBEV IgM antibodies in all samples that were inconclusive based on the commercial IgM-ELISA. Our strep-SP-IgM-ELISA will be useful for diagnoses in TBE-endemic areas.
Investigating Tick-borne Flaviviral-like Particles as a Delivery System for Gene Therapy
2018, Current Therapeutic Research - Clinical and Experimental
Research on the biogenesis of tick-borne encephalitis virus (TBEV) would benefit gene therapy. Due to specific arrangements of genes along the TBEV genome, its viral-like particles (VLPs) could be exploited as shuttles to deliver their replicon, which carries therapeutic genes, to immune system cells.
To develop a flaviviral vector for gene delivery as a part of gene therapy research that can be expressed in secretable VLP suicidal shuttles and provide abundant unique molecular and structural data supporting this gene therapy concept.
TBEV structural gene constructs of a Swedish Torö strain were cloned into plasmids driven by the promoters CAG and CMV and then transfected into various cell lines, including COS-1 and BHK-21. Time-course sampling of the cells, culture fluid, cell lysate supernatant, and pellet specimens were performed. Western blotting and electron microscopy analyses of collected specimens were used to investigate molecular and structural processing of TBEV structural proteins.
Western blotting analysis showed differences between promoters in directing the gene expression of the VLPs constructs. The premature flaviviral polypeptides as well as mature VLPs could be traced. Using electron microscopy, the premature and mature VLP accumulation in cellular compartments—and also endoplasmic reticulum proliferation as a virus factory platform—were observed in addition to secreted VLPs.
The abundant virologic and cellular findings in this study show the natural processing and safety of inserting flaviviral structural genes into suicidal VLP shuttles. Thus, we propose that these VLPs are a suitable gene delivering system model in gene therapy.
Japanese Encephalitis Vaccines
2017, Plotkin's Vaccines
Development of a serodiagnostic multi-species ELISA against tick-borne encephalitis virus using subviral particles
2016, Ticks and Tick-borne Diseases
Tick-borne encephalitis virus (TBEV) is a zoonotic agent causing severe encephalitis in humans. A wide range of animal species could be infected with TBEV in endemic areas. A serological survey of wild animals is effective in identifying TBEV-endemic areas. Safe, simple, and reliable TBEV serodiagnostic tools are needed to test animals. In this study, ELISA was developed to detect anti-TBEV specific antibodies in multi-species of animals, using recombinant subviral particles (SPs) with an affinity tag and protein A/G. A Strep-tag was fused at the N terminus of the E protein of the plasmid coding TBEV prME. The E proteins with Strep-tag were secreted as SPs, of which Strep-tag was exposed on the surface. The tagged E proteins were associated with prM. The SPs with Strep-tag were applied as the antigen of ELISA, and TBEV-specific antibodies were detected by the protein A/G. Compared to neutralization test results, the ELISA showed 96.8% sensitivity and 97.7% specificity in rodents and 95.1% sensitivity and 96.0% specificity in humans, without cross-reactivity with antibodies to Japanese encephalitis virus. These results indicate that our ELISA would be useful to detect TBE-specific antibodies in a wide range of animal species.

View all citing articles on Scopus

¹: Current address: Plum Island Animal Disease Center, Agricultural Research Service, United States Department of Agriculture, Greenport, NY 11944, and Yale Arbovirus Research Unit, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06510.

View full text

Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection

Abstract

Virology

Vaccine

Adv. Virus Res.

Virology

Virology

Virology

Virology

Virology

Virology

Virology

Current approaches to the development of dengue vaccines and related aspects of the molecular biology of flaviviruses

J. Infect. Dis.

Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis

J. Virol.

Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses

Amer. J. Trop. Med. Hyg.

Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue

J. Gen. Virol.

Excretion of hepatitis B surface antigen particles from mouse cells transformed with cloned viral DNA

Virion and soluble antigens of Japanese encephalitis virus

Infect. Immun.

Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a

J. Virol.

Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice

J. Gen. Virol.

Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals

J. Virol.

Expression of envelope glycoprotein (E) of Japanese encephalitis virus by recombinant vaccinia virus

Acta Virol.

Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus

J. Gen. Virol.

Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection

Amer. J. Trop. Med. Hyg.